Pamicell Signs $8.8 Billion Nucleotide Supply Contract with US Thermo Fisher
[Asia Economy Reporter Park Jun-yi] Pharmicell announced on the 28th that it has signed a sales and supply contract for the pharmaceutical intermediate 'nucleoside' worth $7,923,500 (approximately 8.78637 billion KRW) with Thermo Fisher Scientific, a U.S. life sciences company.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- $800 Million Oil Trades Just Before Trump Announcement... U.S. Authorities Launch Investigation
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
- "Am I Really in the Top 30%?" and "Worried About My Girlfriend in the Bottom 70%"... Buzz Over High Oil Price Relief Fund
- "It Has Now Crossed Borders": No Vaccine or Treatment as Bundibugyo Ebola Variant Spreads [Reading Science]
The contract amount accounts for 27.05% of the sales as of the end of last year. The contract will expire on August 13 of next year.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
